Warfarin Dosing Biomarkers Could Be Model For Genetic Tests In Labeling

The development of standards for a warfarin dosing biomarker under a collaboration with the C-Path Institute could pave the regulatory pathway for markers involving other therapeutic agents

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet